Is This Gene-Editing Stock Doomed? [The Motley Fool]
Sangamo Therapeutics, Inc. (SGMO)
Last sangamo therapeutics, inc. earnings: 2/28 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sangamo.com
Company Research
Source: The Motley Fool
Investors had high expectations of the first clinical trial to edit the DNA of living humans, but they came away with concerns. Sangamo Therapeutics ( NASDAQ:SGMO ) made history on September 5 when it announced preliminary results from the first-ever clinical trial evaluating in vivo gene editing in humans, but the stock crashed, losing almost a quarter of its value that day. You would think from the market reaction that the trial was failure, but although the trial is not complete yet, so far, it's meeting the primary objective and two of the three secondary objectives. Is the market reaction an early indication that Sangamo's approach will end in disappointment? The CRISPR/Cas9 gene-editing technology has garnered a lot attention from investors because it is a relatively new and very powerful technique that has the potential to revolutionize medicine by making the discovery of gene-based therapies relatively cheap and easy. But Sangamo uses a technology called zinc
Show less
Read more
Impact Snapshot
Event Time:
SGMO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SGMO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SGMO alerts
High impacting Sangamo Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SGMO
News
- What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering [Yahoo! Finance]Yahoo! Finance
- Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct OfferingBusiness Wire
- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.00 price target on the stock, up previously from $3.00.MarketBeat
- Sangamo Therapeutics, Inc. (NASDAQ: SGMO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.MarketBeat
SGMO
Earnings
- 3/13/24 - Miss
SGMO
Sec Filings
- 3/25/24 - Form 8-K
- 3/25/24 - Form 424B5
- 3/13/24 - Form 8-K
- SGMO's page on the SEC website